MARKER THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
MARKER THERAPEUTICS, INC. (MRKR) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $15.45 million for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2017-03-14
- MARKER THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2015 was $15.45M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|
| 2015-12-31 | $15.45M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |